JP2018538356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538356A5 JP2018538356A5 JP2018536700A JP2018536700A JP2018538356A5 JP 2018538356 A5 JP2018538356 A5 JP 2018538356A5 JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018538356 A5 JP2018538356 A5 JP 2018538356A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- igf
- mutations
- bispecific protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 230000035772 mutation Effects 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 24
- 102000004121 Annexin A5 Human genes 0.000 claims 13
- 108090000672 Annexin A5 Proteins 0.000 claims 13
- 230000008685 targeting Effects 0.000 claims 12
- 210000001519 tissue Anatomy 0.000 claims 12
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 10
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 8
- 239000012190 activator Substances 0.000 claims 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 6
- 102000044162 human IGF1 Human genes 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 5
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 claims 4
- 210000000170 cell membrane Anatomy 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 102000054215 human ANXA5 Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000026731 phosphorylation Effects 0.000 claims 4
- 238000006366 phosphorylation reaction Methods 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000017423 tissue regeneration Effects 0.000 claims 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 101710150709 Serine/threonine-protein kinase B Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 230000009087 cell motility Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021159345A JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236169P | 2015-10-02 | 2015-10-02 | |
| US62/236,169 | 2015-10-02 | ||
| US201562237889P | 2015-10-06 | 2015-10-06 | |
| US62/237,889 | 2015-10-06 | ||
| US201662322910P | 2016-04-15 | 2016-04-15 | |
| US62/322,910 | 2016-04-15 | ||
| PCT/US2016/054744 WO2017059231A1 (en) | 2015-10-02 | 2016-09-30 | Bi-specific therapeutic proteins for tissue repair |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021159345A Division JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538356A JP2018538356A (ja) | 2018-12-27 |
| JP2018538356A5 true JP2018538356A5 (enExample) | 2019-12-26 |
| JP7005019B2 JP7005019B2 (ja) | 2022-02-04 |
Family
ID=58427983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536700A Active JP7005019B2 (ja) | 2015-10-02 | 2016-09-30 | 組織修復のための二重特異性治療用タンパク質 |
| JP2021159345A Active JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021159345A Active JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US10040840B2 (enExample) |
| EP (2) | EP3355907B1 (enExample) |
| JP (2) | JP7005019B2 (enExample) |
| CN (2) | CN108367048B (enExample) |
| CA (1) | CA3000742A1 (enExample) |
| ES (1) | ES2863278T3 (enExample) |
| WO (1) | WO2017059231A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9238080B2 (en) * | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| EP3355907B1 (en) | 2015-10-02 | 2021-01-20 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| CN111763680A (zh) * | 2019-05-22 | 2020-10-13 | 杭州杰迪生物科技有限公司 | 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞 |
| JP7355326B2 (ja) * | 2019-08-05 | 2023-10-03 | デンカ株式会社 | 経粘膜投与薬剤 |
| CA3152500A1 (en) * | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
| CN112584507B (zh) | 2019-09-30 | 2022-05-17 | 华为技术有限公司 | 一种数据处理方法、装置及存储介质 |
| CN115379850A (zh) | 2019-12-24 | 2022-11-22 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| CN111195350A (zh) * | 2020-01-15 | 2020-05-26 | 重庆大学 | IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用 |
| EP4188410B1 (en) * | 2020-07-30 | 2025-11-05 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for use in the treatment of central nervous system disorders |
| WO2022263407A2 (en) | 2021-06-14 | 2022-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes |
| CA3223707A1 (en) | 2021-06-21 | 2022-12-29 | Hanadie Yousef | Regenerative polypeptides and uses thereof |
| US20240279359A1 (en) * | 2021-06-30 | 2024-08-22 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for targeted delivery of growth factors to the glomerulus |
| EP4479417A4 (en) * | 2022-02-15 | 2025-12-10 | Silver Creek Pharmaceuticals Inc | Chimeric proteins for the treatment of acute radiation syndrome |
| WO2025207443A1 (en) * | 2024-03-25 | 2025-10-02 | Cavalry Biosciences, Inc. | Igf-1-related compositions and uses of the same |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL269416A (enExample) | 1960-09-21 | |||
| GB8819826D0 (en) | 1988-08-20 | 1988-09-21 | Kabivitrum Ab | Glycosylated igf-1 |
| US5679771A (en) | 1990-02-13 | 1997-10-21 | Gropep Pty. Ltd. | Method for treating intestinal diseases |
| AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
| US5632986A (en) | 1991-05-09 | 1997-05-27 | The University Of Washington | Phospholipid-targeted thrombolytic agents |
| US5444045A (en) * | 1992-09-17 | 1995-08-22 | Gropep, Pty. Ltd. | Method of administering IGF-1, IGF-2, and analogs thereof to birds |
| JP3664727B2 (ja) * | 1994-01-24 | 2005-06-29 | ネオルクス コーポレイション | 放射標識したアネキシン |
| EP0756494A1 (en) | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| AU2676297A (en) | 1996-04-17 | 1997-11-07 | Neurocrine Biosciences, Inc. | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| CA2331789C (en) | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6387663B1 (en) | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| JP2002535967A (ja) | 1999-01-06 | 2002-10-29 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子（ｉｇｆ）ｉ変異体 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2001007059A1 (en) | 1999-07-21 | 2001-02-01 | University Of Southern California | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| JP2001251104A (ja) | 2000-03-03 | 2001-09-14 | Murata Mfg Co Ltd | 非可逆回路素子及び通信機装置 |
| ES2346185T3 (es) | 2000-08-29 | 2010-10-13 | Aurogen Incorporated | Metodo para tratar el sistema nervioso central mediante la administracion de analogos estructurales de igf. |
| ES2344592T3 (es) | 2001-01-05 | 2010-09-01 | Pfizer Inc. | Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i. |
| US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| EP1974752B1 (en) | 2001-04-30 | 2012-09-26 | BioMarin Pharmaceutical Inc. | Subcellular targeting of therapeutic proteins |
| US7049286B2 (en) | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
| AU2008200706B2 (en) | 2001-10-16 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7576186B2 (en) | 2002-04-23 | 2009-08-18 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| WO2003103577A2 (en) | 2002-06-06 | 2003-12-18 | Tze Chein Wun | Novel recombinant anticoagulant proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040213738A1 (en) | 2003-03-31 | 2004-10-28 | Susan Croll-Kalish | CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity |
| WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
| AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
| BRPI0510716A (pt) | 2004-05-05 | 2007-11-20 | Merrimack Pharmaceuticals Inc | uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit |
| WO2006004910A2 (en) | 2004-06-28 | 2006-01-12 | Transtarget Inc. | Improved bispecific antibodies |
| US7511016B2 (en) | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| JP2008510732A (ja) | 2004-08-20 | 2008-04-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 心臓組織の損傷を処置、予防、阻害、または緩和する方法 |
| JP2008517917A (ja) * | 2004-10-21 | 2008-05-29 | アイジーエフ オンコロジー エルエルシー | 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド |
| EP1833847B1 (en) * | 2005-01-07 | 2011-07-20 | Regeneron Pharmaceuticals, Inc. | Igf-1 fusion polypeptides and therapeutic uses thereof |
| WO2006076525A2 (en) | 2005-01-14 | 2006-07-20 | Cytogen Corporation | Combination cancer therapy with anti-psma antibodies |
| CA2591914C (en) | 2005-01-24 | 2017-04-25 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
| BRPI0519897A2 (pt) | 2005-02-23 | 2009-08-18 | Merrimack Pharmaceuticals Inc | método para modular a atividade ou atividades biológicas de moléculas alvo em uma célula alvo, agente de ligação biespecìfico, composição, uso de um agente de ligação biespecìfico, e, kit |
| US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| WO2006128125A2 (en) | 2005-05-27 | 2006-11-30 | Five Prime Therapeutics, Inc. | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| DK1960790T3 (en) | 2005-12-12 | 2017-03-06 | Mosamedix Bv | ANNEXIN DERIVATIVES SUITABLE FOR PREGNANCY FOR TREATMENT AND DIAGNOSIS |
| US7776816B2 (en) | 2006-01-20 | 2010-08-17 | Board Of Regents, The University Of Texas System | Preserving hypoxic tissue |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| AU2007255419A1 (en) | 2006-06-09 | 2007-12-13 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| US9187517B2 (en) | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| SE530073C2 (sv) | 2007-01-23 | 2008-02-26 | Teknikbolaget K Samuelsson Ab | Sprutmunstycksanordning för brandsläckningssystem |
| US8003761B2 (en) | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US8889140B2 (en) | 2007-05-31 | 2014-11-18 | Transtarget, Inc. | Compositions and methods for tissue repair |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| ES2422007T3 (es) | 2007-06-21 | 2013-09-06 | Univ Muenchen Tech | Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro |
| WO2009030720A2 (en) | 2007-09-06 | 2009-03-12 | Novozymes Biopharma Dk A/S | Process for producing a recombinant protein |
| CN102057054B (zh) | 2008-04-11 | 2015-06-10 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| CA2751068A1 (en) * | 2009-01-31 | 2010-08-05 | Igf Oncology, Llc | Anti-cancer protein-platinum conjugates |
| RU2511577C2 (ru) | 2009-07-22 | 2014-04-10 | Ипсен Фарма С.А.С. | Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59 |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| WO2011047180A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
| US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| WO2012078153A1 (en) | 2010-12-08 | 2012-06-14 | Viacyte, Inc. | Agents and methods for inhibiting human pluripotent stem cell growth |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013086786A1 (zh) | 2011-12-15 | 2013-06-20 | Qin Shulin | 具有降血糖作用的化合物、组合物及其用途 |
| WO2014052451A2 (en) | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Insulin analog dimers |
| KR20150134417A (ko) | 2013-03-29 | 2015-12-01 | 메리맥 파마슈티컬즈, 인크. | 연골-결합 융합 단백질 |
| AU2015204540B2 (en) | 2014-01-12 | 2020-03-19 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| EP3355907B1 (en) | 2015-10-02 | 2021-01-20 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
-
2016
- 2016-09-30 EP EP16852701.8A patent/EP3355907B1/en active Active
- 2016-09-30 JP JP2018536700A patent/JP7005019B2/ja active Active
- 2016-09-30 WO PCT/US2016/054744 patent/WO2017059231A1/en not_active Ceased
- 2016-09-30 CN CN201680070850.6A patent/CN108367048B/zh active Active
- 2016-09-30 EP EP21152085.3A patent/EP3865147B1/en active Active
- 2016-09-30 ES ES16852701T patent/ES2863278T3/es active Active
- 2016-09-30 CN CN202210868944.5A patent/CN115960249A/zh active Pending
- 2016-09-30 CA CA3000742A patent/CA3000742A1/en active Pending
- 2016-09-30 US US15/281,795 patent/US10040840B2/en active Active
-
2018
- 2018-07-03 US US16/026,319 patent/US10633425B2/en active Active
-
2020
- 2020-03-17 US US16/820,960 patent/US11155593B2/en active Active
-
2021
- 2021-09-28 US US17/487,120 patent/US11879002B2/en active Active
- 2021-09-29 JP JP2021159345A patent/JP7365715B2/ja active Active
-
2022
- 2022-02-10 US US17/668,825 patent/US12122819B2/en active Active
-
2024
- 2024-09-17 US US18/887,949 patent/US20250145682A1/en active Pending